Transport characteristics of candesartan in human intestinal Caco-2 cell line

Biopharmaceutics and Drug Disposition

Volumn 30, Issue 5, 2009, Pages 259-264

  Zhou, Lingjie ^a   Chen, Xiaoping ^a   Gu, Yuanqing ^a   Liang, Jianying ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Caco 2 cells; Candesartan; Intestinal absorption; P glycoprotein

Indexed keywords

CANDESARTAN; CYCLOSPORIN A; VERAPAMIL; ANGIOTENSIN RECEPTOR ANTAGONIST; BENZIMIDAZOLE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARRIER PROTEIN; CYCLOSPORIN; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; TETRAZOLE DERIVATIVE;

ARTICLE; CELL PH; CELL STRAIN CACO 2; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFUSION; DRUG TRANSPORT; DRUG UPTAKE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTESTINE MUCOSA; ACTIVE TRANSPORT; DOSE RESPONSE; DRUG ANTAGONISM; METABOLISM; PH;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BIOLOGICAL TRANSPORT, ACTIVE; CACO-2 CELLS; CALCIUM CHANNEL BLOCKERS; CARRIER PROTEINS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROGEN-ION CONCENTRATION; IMMUNOSUPPRESSIVE AGENTS; P-GLYCOPROTEIN; TETRAZOLES; VERAPAMIL;

EID: 70349768927     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.664     Document Type: Article

References (17)

1. Michel B. Angiotensin II type 1 receptor blockers. Circulation 2001; 103: 904-912.
2. Ripley TL, Chonlahan JS, Germany RE. Candesartan in heart failure. Clin Interv Aging 2006; 1: 357-366.
3. Sharon S, Alexandra LS. Candesartan cilexetil: An angiotensin II-receptor blocker. Am J Health Syst Pharm 2000; 157: 739-746.
4. 1 receptor blockers in the treatment of arterial hypertension. Am J Ther 2003; 10: 401-408.
5. Bakris G. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. Clin Hypertens 2001; 3: 16-21.
6. Gleiter CH, Morike KE. Clinical pharmacokinetics of candesartan. Clin Pharmacokinet 2002; 41: 7-17.
7. 1) receptor blockers in hypertension. J Hum Hypertens 2000; 14(Suppl 1): S73-S86.
8. Hubner R, Hogemann AM, Sunzel M, et al. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997; 11(Suppl 2): S19-S25.
9. Hochman JH, Yamazaki M, Ohe T, et al. Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein. Curr Drug Metab 2002; 3: 257-273.
10. Braun A, Hammerle S, Suda K, et al. Cell cultures as tools in biopharmacy. Eur J Pharm Sci 2000; 11 (Suppl 2): S51-S60.
11. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
12. Soldner A, Benet LZ, Mutschler E, et al. Active transport of the angiotensin-II antagonist losartan and its main metabolite EXP 3174 across MDCK-MDR1 and Caco-2 cell monolayers. Br J Pharmacol 2000; 129: 1235-1243.
13. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 2001; 46: 27-43.
14. Varma MV, Ashokraj Y, Dey CS, et al. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res 2003; 48: 347-359.
15. Hunter J, Hirst BH. Intestinal secretion of drugs. The role of P-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv Drug Deliv Rev 1997; 25: 129-157.
16. 1) gene polymorphism. Ther Drug Monit 2004; 26: 180-185.
17. 1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004; 75: 13-33.